Market Mover: Geovax Labs (GOVX) Rises at Midday August 5

Equities Staff  |

Geovax Labs Inc (NASDAQ: GOVX) shares moved 27.19%, or $0.745 per share, as on 11:57:12 est today. Opening the day at $3.34, 33,394,099 shares of Geovax Labs have been traded today and the stock has moved between $3.88 and $3.28.  

Already this year the company has a YTD change of 1.38%.

Geovax Labs anticipates its next earnings on 2022-11-10.

For technical charts, analysis, and more on Geovax Labs visit the company profile.

About Geovax Labs Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

To get more information on Geovax Labs Inc and to follow the company's latest updates, you can visit the company's profile page here: Geovax Labs Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content